Search
Menu
Home
HTB
2009
February
HTB
February 2009
Contents
Editorial
Volume 10 Number 1/2 Jan/Feb 2009
Conference reports
9th International Congress on Drug Therapy in HIV Infection, 9-13 November 2008, Glasgow
Summary of antiretroviral studies at Glasgow
The Antiretroviral Pregnancy Registry: individual drug safety reports on health of infants exposed to ARVs during pregnancy
Initial results from PENTA 11 trial of planned treatment interruption
Inflammation and coagulation markers askew in children with higher HIV RNA
Dosing of lopinavir/ritonavir in the CHIPS cohort
Number needed to treat to harm (NNTH) analysis of impact of underlying cardiovascular factors on risk of abacavir-related heart attack
Bone disease and HIV
Renal tubule damage with tenofovir despite normal glomerular function
10th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, 6-8 November 2008, London, UK
Report from the 10th IWADRLH by Jacqueline Capeau
Report from the 10th IWADRLH by Michael Dubé
Impact of body changes on the quality of life of HIV-positive treatment-experienced patients: an online community-based survey
Antiretrovirals
Increased atazanavir dose recommended when used in combination with efavirenz or Atripla in naive patients
EMEA approves once-daily darunavir/ritonavir (800mg/100mg) for treatment-naive patients in Europe
Maraviroc safety label changes included with US traditional approval
US approval of paediatric abacavir
EMEA supports extension of D:A:D study until at least 2012 and the new remit to include non-AIDS cancers and kidney disease
Applications to approve non-refrigerated ritonavir submitted to EMEA and FDA
Treatment access
Lost benefit of ARVs in South Africa
PK and drug interactions
Elvitegravir with tipranavir/ritonavir or darunavir/ritonavir
Serum bilirubin increases when PEG-interferon and ribavirin are used with atazanavir
Drug interactions with integrase inhibitors
Drug interactions between efavirenz and itraconazole
Effect on tacrolimus when switching from nelfinavir to fosamprenavir
Cure-related research
Cause for caution on HIV cure report
Basic science and immunology
Low-level HIV replication versus latency: identifying the source of viral rebounds during treatment interruption
Other news
Martin Delaney, leading treatment activist and founder of Project Inform, dies at 63
Report refutes HIV denialist claims on childrens HIV trials
International AIDS Conference to be held in the US after over 20-year ban
Changes at the European Medicines Agency (EMA)
On the web
39th Union World Conference on Lung Health
Management of hepatitis B: consensus statement and data review
PLoS medicine and PLoS clinical trials
PDFs
Volume 10 Number 1/2 Jan/Feb 2009 PDF
HTB RSS
Early access
Future PrEP and new results from PURPOSE 1 and 2: does HIV exposure explain incident cases?
21 November 2024
Glasgow HIV Congress 2024
10 November 2024
Unheard: The medical practice of silencing – by Dr Rageshri Dhairyawan
9 November 2024
Bipolar disorder in people living with HIV
1 November 2024
All early access reports
Current issues
November 2024
October 2024
September 2024
Back issues
Special report
HTB news: i-Base changes during 2024
1 November 2024
More from HTB
Conference reports
Conference shortcuts
Articles by subject
PDFs
Subscribe
HTB homepage
Home
i-Base homepage
Donate